17-04-2023

Cinquième séminaire du laboratoire de recherche sur le diabète

Programme

Liste des communications :

FIRST SESSION:

  • EULAR recommendations for the management of rheumatoid arthritis- 2022 UPDATE. Dr Sendani Doha →   [PDF]

  • Recommendations for the management of axial spondyloarthritis: update ASAS-EULAR 2022. Dr Boudalia Lwiza →   [PDF]

  • Cardiovascular screening on patients with rhumatoid arthritis. Dr Cherif Benmoussa Fadia →   [PDF]

SECOND SESSION:

  • Continuos Glucose Monitoring. Pr Lounici Ali →   [PDF]

  • Real-life use of self-monitoring of blood glucose in our patients with type 1 diabetes. Brahmi Yasmina →   [PDF]

  • Inhibitors of SGLT2. Dr Bensefia Amel →   [PDF]

  • Essentials on Diabetes of ADA/EASD 2022. Dr Bestaoui Mohamed Hadi →   [PDF]

THIRD SESSION:

  • Liver fibrosis. Dr Bouabdellah Nesrine →   [PDF]

  • Effect of periodontal treatment on glycemic control in diabetic patients. Dr Bensaidi Sofiane→   [PDF]

  • Effects of a new formulation of oral insulin on hemostasis alterations in type 1 diabetics. Kaddour Nawel & al. →   [PDF]

FOURTH SESSION:

  • Antiphospholid syndrome : what’s new ? Pr Taouli Katia →   [PDF]

  • ANCA-associated vasculitis_How to Treat (HOT). Dr Bestaoui Mohamed Hadi →   [PDF]

  • Eosinophilicvascularitis. Dr Boulenouar Fatima-Zohra →   [PDF]

  • Sarcoidosis: an update for internists. Dr Bensefia Amel →   [PDF]

FIFTH SESSION:

  • Juvenile idiopathic arthritis & adult-onset Still´s disease. Dr Tchenar Sihem →   [PDF]

  • IgG4 associated disease. Dr Rais Ibtissem →   [PDF]

  • Vaccines in rheumatic musculoskeletal diseases (RMDs). Dr Miloud Siffi Djamila →   [PDF]

SIXTH SESSION:

  • Clinical challenges in SLE. Dr Brahmi Yasmina →   [PDF]

  • Lupus nephritis. Dr Mahi Djaouida→   [PDF]

  • Treatment of gastrointestinal manifestations of scleroderma and myositis. Dr Benmostefa Meriem→   [PDF]

  • Essentials on Hypertension of AHA/EHA 2022. Pr Lounici Ali →   [PDF]

SEVENTH SESSION: Symposia Novo Nordisk : L’Hypoglycémie chez le patient diabétique type 2 sous basal bolus et comment réduire le risque avec NovoRapid. Pr Lounici Ali →   [PDF]